ABITEC announces extension of product portfolio and enters new market
Posted: 19 September 2016 | | 1 comment
ABITEC Corporation continues to add new innovations and dosage form applications to their already expansive product portfolio…
ABITEC’s R&D continues to develop innovative products that meet the ever evolving demands of the pharmaceutical market. The expansion of their non-ionic High HLB surfactant line, ACCONON®, offers a product that can be used in solid formulation as a high melt emulsifier and bioavailability enhancer. ABITEC is also introducing to market their first line of functional lipid excipients for parenteral applications, INJECTA™.
Rick Kettinger, Global Business Unit Director – Pharmaceutical and Nutritional Health for ABITEC said, “Utilization of our core capabilities and expert technical staff to develop the right products for the market is what we do best. We strive to increase our customer’s formulating options, with high-quality products that meet the needs of their application.”
Technical highlights include: ABITEC Corporation
ACCONON® C-50 EP/NF*
ACCONON® C-50 EP/NF is mixed mono-, di- and triglycerides of hydrogenated palm oil and Macrogol palmitate/stearate and meets the requirements of current European Pharmacopoeia (EP) and United States
Pharmacopeia/National Formulary (USP/NF) Monographs for Stearoyl Macrogolglycerides / Stearoyl Polyoxylglycerides.
INJECTA™ Lipid Excipients*
The new INJECTA™ parenteral grade lipid excipients provide improved solubilization for injectable actives. The INJECTA grade portfolio of products include; CAPTEX® medium chain triglycerides and CAPMUL® mono- and di-glycerides, manufactured specifically for use in injectable formulations. These products meet and comply with specified monographs**.
Product Name | Chemical Name | Appearance/Form | Application/Functionality |
ACCONON C-50 EP/NF | PEG-50 Hydrogenated Palm Glycerides | Solid | • Solid Dispersions • Physical Mixtures • Surfactants • Hot melt granulation for amorphous drug delivery and/or sustained release |
CAPTEX INJ 355 EP/NF/JPE
| Caprylic/Capric Glycerides | liquid | • Improved solubility for BCS II and IV APIs • Controlled Release |
CAPTEX INJ 300 Low C6 EP/NF/JPE | Caprylic/Capric Glycerides | liquid | • Improved solubility for BCS II and IV APIs • Controlled Release |
CAPMUL INJ MCM EP | Caprylic/Capric Glycerides | Liquid or solid | • Improved solubility for BCS II and IV APIs • Controlled Release |
* Developmental
**Monographs per product are noted in the chart above
Can I get some literature on the ratio API/ACCONON C-50 EP/NF in HME?
Thanks
Carmen
CARMEN POPESCU, PhD
SENIOR PROJECT COORDINATOR
PHARMACEUTICAL APPLICATIONS
Roquette America Inc.
2211 Innovation Dr., Geneva, IL 60134
Phone: (630) 463-9436 FAX: (630) 232-2157
Cell: 319 795 2482
[email protected]
http://www.roquettepharma.com
http://www.roquette.com
https://www.researchgate.net/profile/Carmen_Popescu3